Phenibut: the case for state action

Phenibut is not approved by the FDA for any use, and the FDA has determined that it does not meet the statutory definition of a dietary ingredient — which means it is already unlawful to sell as a dietary supplement, and has been since at least 2019. It is nonetheless sold openly online and in retail shops across the country. At the federal level this is an enforcement gap, not a legislative gap. State scheduling closes it at the point of sale, where enforcement is practical.^[2,3]

The practical consequence for a bill sponsor is that a state scheduling action is not a novel policy position. It enforces a determination the federal government has already made.

Dietary ingredient status

The FDA has published a position stating that phenibut does not meet the definition of a dietary ingredient under the Federal Food, Drug, and Cosmetic Act. A product that declares phenibut as a dietary ingredient is therefore misbranded.^[3]

The 2019 warning letters

In April 2019 the FDA announced action against dietary supplements containing phenibut, issuing warning letters to companies marketing it as a supplement and stating that those products are misbranded.^[2]

This is the section most likely to be quoted, so it is also the section held to the strictest standard on this site: a jurisdiction appears below only if we opened the statute and read the text ourselves. Secondary sources disagree with each other about which states have acted, and two widely repeated claims did not survive checking.

Ohio is the home state of this project, so it gets its own section and the same evidentiary standard as every other row above — which means being straightforward about what we have not yet confirmed.

Ohio’s controlled substance schedules are set out in Ohio Revised Code § 3719.41, with authority for the State Board of Pharmacy to recommend changes and a rule-making pathway under ORC Chapter 3719. We were not able to retrieve the complete schedule text from the official publication in a form we could verify, so this page does not assert either that Ohio has scheduled phenibut or that it has not.

What an Ohio scheduling action would require, in outline: an amendment to the schedules in ORC § 3719.41 naming phenibut, or an administrative scheduling action through the State Board of Pharmacy. Health-policy jurisdiction in the General Assembly sits with the House Health Committee and the Senate Health Committee. Confirm current committee assignment and the Board’s present rule-making posture with Legislative Service Commission staff before relying on it — committee jurisdiction changes between General Assemblies and this page is not a substitute for LSC.

“This is overbroad — it will sweep in ordinary supplements.”

It will not, because a scheduling action names a single compound. Phenibut is not a vitamin, a mineral, a botanical, an amino acid, or a dietary substance used to supplement the diet. The FDA has already made that determination.^[3] A bill naming phenibut affects phenibut.

“Consumers should be free to choose.”

The consumer-choice argument assumes an informed consumer. Phenibut is sold as a bulk powder with purity claims and without any statement that it causes physical dependence, that tolerance develops within weeks, or that stopping can produce psychosis requiring hospitalisation.^[5,7] The choice being defended is one made without the material facts.

“The numbers are small.”

They are, and this site says so first.^[1] 1,320 reported exposures over eleven years is not a large number. Two things are worth putting alongside it. First, the severity rate inside that number is high: roughly one in eight reported exposures was life-threatening or disabling. Second, 85% of those calls came from healthcare facilities, so the denominator counts people who already reached a hospital and excludes everyone who developed dependence quietly. The figure is a floor.

“Is there really a mechanism, or just anecdote?”

The mechanism is well characterised: phenibut is a GABA-B agonist, structurally related to baclofen, and its withdrawal syndrome resembles that of alcohol and benzodiazepines.^[4,11] The weakness in the evidence base is not mechanistic plausibility; it is that the clinical literature consists of case reports rather than controlled studies, as the 2023 systematic review states plainly.^[11]

A printable one-page brief is generated from this page’s own source content at build time, so it cannot drift out of sync with what you have just read.

Open the one-page brief (opens in a new tab; use your browser’s Print to PDF to produce the leave-behind)

This page is also laid out to print directly. Printing it produces the full argument with citations and URLs rendered in full.

1. Graves JM, Dilley J, Kubsad S, Liebelt E. Notes from the Field: Phenibut Exposures Reported to Poison Centers — United States, 2009–2019. MMWR Morbidity and Mortality Weekly Report. 2020;69(35):1227–1228. doi:10.15585/mmwr.mm6935a5. cdc.gov/mmwr (PMID 32881852)
2. FDA acts on dietary supplements containing DMHA and phenibut. U.S. Food and Drug Administration, Constituent Update. 2019. fda.gov
3. Phenibut in Dietary Supplements. U.S. Food and Drug Administration. n.d.. fda.gov
4. Lapin I. Phenibut (β-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Reviews. 2001;7(4):471–481. doi:10.1111/j.1527-3458.2001.tb00211.x. PMID 11830761
5. Owen DR, Wood DM, Archer JR, Dargan PI. Phenibut (4-amino-3-phenyl-butyric acid): availability, prevalence of use, desired effects and acute toxicity. Drug and Alcohol Review. 2016;35(5):591–596. doi:10.1111/dar.12356. PMID 26693960
6. Phenibut: a recreational drug with abuse potential. National Capital Poison Center (Poison Control). n.d.. poison.org
7. Esposito CM, Mandolini GM, Delvecchio G, Fiorentini A, Brambilla P. Psychomotor agitation non-responsive to treatment: a case report of phenibut withdrawal syndrome. Frontiers in Psychiatry. 2021;12:688147. doi:10.3389/fpsyt.2021.688147. PMID 34262493
8. Joshi YB, Friend SF, Jimenez B, Steiger LR. Dissociative intoxication and prolonged withdrawal associated with phenibut: a case report. Journal of Clinical Psychopharmacology. 2017;37(4):478–480. doi:10.1097/JCP.0000000000000731. PMID 28614159
9. Zheng KH, Khan A, Espiridion ED. Phenibut addiction in a patient with substance use disorder. Cureus. 2019;11(7):e5230. doi:10.7759/cureus.5230. PMID 31565631
10. Nedzlek CD, Michaelis A. An unusual presentation of an uncommon drug: a case report on phenibut overdose. Cureus. 2022;14(4):e23913. doi:10.7759/cureus.23913. PMID 35530906
11. Feldman R, Autry B, Dukes J, Lofy T, Marchetti G, Patt A, Batterman N, Theobald J. A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance versus polysubstance withdrawal. Clinical Toxicology. 2023;61(11):941–951. doi:10.1080/15563650.2023.2285702. PMID 38112312
12. Bonnet U, Scherbaum N, Schaper A, Soyka M. Phenibut — an illegal food supplement with psychotropic effects and health risks. Deutsches Ärzteblatt International. 2024;121(7):222–227. doi:10.3238/arztebl.m2024.0003. PMID 38377332
13. House Bill 2 (enrolled), amending Ala. Code § 20-2-25 to add phenibut to Schedule II. Alabama Legislature, 2021 Regular Session. 2021. Enrolled act (PDF)
14. Fla. Stat. § 893.03, Standards and schedules. The Florida Senate, 2024 Florida Statutes. 2024. flsenate.gov
15. Iowa Code ch. 124, Controlled Substances (schedules I–V). Iowa Legislature. 2025. legis.iowa.gov